Sucampo Pharmaceuticals, Inc.
) recently received a milestone payment of $10 million from
Takeda Pharmaceutical Company Limited
). The payment was in accordance with a licensing and
collaboration agreement between the two companies. The milestone
payment was earned on the commercial launch of Amitiza in the US
for the treatment of opioid-induced constipation (OIC) in adults
with chronic, non-cancer pain.
Sucampo and Takeda's association goes back to Oct 2004 when
the companies collaborated for the development and
commercialization of Amitiza in the US and Canada. According to
the agreement, Sucampo stands to receive up to $50 million toward
development costs for each additional indication and $20 million
for each additional formulation.
All costs will be shared equally thereafter. Takeda has paid a
total of $104.7 million toward research and development
reimbursement as of Dec 31, 2012.
Amitiza was approved by the US Food and Drug Administration
(FDA) in 2006 for chronic idiopathic constipation (CIC) in
adults. Furthermore, it gained FDA approval in 2008 for irritable
bowel syndrome with constipation (IBS-C) in adult women.
Amitiza is approved for CIC in Switzerland as well as the UK
and for chronic constipation (CC) in Japan. Sucampo reported
$64.9 million US net sales of Amitiza in the first quarter of
2013. Amitiza currently holds the status of being the only oral
approved therapy for OIC in adult patients with chronic,
Several companies like
Salix Pharmaceutical Ltd.
Progenics Pharmaceuticals, Inc.
) are developing candidates for OIC in patients with chronic
Sucampo currently carries a Zacks Rank #3 (Hold). Meanwhile,
Salix Pharma looks well-positioned with a Zacks Rank #1 (Strong
PROGENICS PHARM (PGNX): Free Stock Analysis
SUCAMPO PHARMAC (SCMP): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
TAKEDA PHARMACT (TKPYY): Get Free Report
To read this article on Zacks.com click here.